Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.
Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.
复制标题
DOI：
10.1016/j.cmi.2021.07.024
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
Bisoffi Z
中科院分区：
文献类型：
--
作者：
Buonfrate D;Piubelli C;Gobbi F;Martini D;Bertoli G;Ursini T;Moro L;Ronzoni N;Angheben A;Rodari P;Cardellino C;Tamarozzi F;Tais S;Rizzi E;Degani M;Deiana M;Prato M;Silva R;Bisoffi Z
评估一组医护人员（HCW）对BNT 162 b2 mRNA COVID-19疫苗的抗体应答，比较既往感染过严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）的个体和SARS-CoV-2初治个体。在T0（首次给药当天）、T1（第二次给药当天）和T2（第二次给药后2-3周）检测HCW的IgG抗核衣壳蛋白、IgM抗刺突蛋白和IgG抗受体结合域（IgG-RBD-S）。比较4个主要组之间的抗体应答：A组，既往感染且基线抗体阳性的个体; B组，具有相同病史但抗体阴性的个体; C组，无感染史但抗体阳性的个体; D组，未感染个体。重复测量分析用于比较不同时间点的结果。共纳入1935件HCW。A组的中位IgG-RBD-S滴度显著较高（232人）比B组（56名个体）均在T1（A：22 763 Au/mL，四分位距（IQR）14 222-37 204 Au/mL; B：1373 Au/mL，IQR 783-3078 Au/mL，p 0.0003）和T2（A：30 765 Au/mL，IQR 19 841-42 813 Au/mL; B：13 171 Au/mL，IQR 2324-22 688 Au/mL，p 0.0038）和D组（1563例个体; T1时796 Au/mL，IQR 379-1510 Au/mL; T2时15 494 Au/mL，IQR 9122-23 916 Au/mL，两个时间点的p < 0.0001）。A组的T1值也显著高于D组的T2值（p < 0.0001）。出现症状、年龄较小和女性与较强的抗体应答相关。3月份感染的HCW显示出明显更强的反应，（T1：35 324 Au/mL，IQR 22 003-44 531 Au/mL; T2：37 648 Au/mL，IQR 27 088-50 451 Au/mL）比11月份感染的（T1：18 499 Au/mL，IQR 11 492-27 283 Au/mL; T2：23 210 Au/mL，IQR 18 074-36 086 Au/mL，两个时间点的p < 0.0001。有SARS-CoV-2感染史的个体在一次疫苗注射后产生了强烈的抗体反应。无论感染后的时间长短，单次给药对该组患者可能足够;然而，需要研究与抗体应答的临床相关性。
To assess the antibody response to BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers (HCW), comparing individuals with previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and SARS-CoV-2-naive individuals. HCW were tested at T0 (day of first dose), T1 (day of second dose) and T2 (2–3 weeks after second dose) for IgG anti-nucleocapsid protein, IgM anti-spike protein and IgG anti-receptor binding domain (IgG-RBD-S). The antibody response was compared between four main groups: group A, individuals with previous infection and positive antibodies at baseline; group B, individuals with the same history but negative antibodies; group C, individuals with no infection history but positive antibodies; group D, naive individuals. Repeated measures analysis was used to compare results over time-points. A total of 1935 HCW were included. Median IgG-RBD-S titre was significantly higher for group A (232 individuals) than for group B (56 individuals) both at T1 (A: 22 763 AU/mL, interquartile range (IQR) 14 222–37 204 AU/mL; B: 1373 AU/mL, IQR 783–3078 AU/mL, p 0.0003) and T2 (A: 30 765 AU/mL, IQR 19 841–42 813 AU/mL; B: 13 171 AU/mL, IQR 2324–22 688 AU/mL, p 0.0038) and for group D (1563 individuals; 796 AU/mL, IQR 379–1510 AU/mL at T1; 15 494 AU/mL, IQR 9122–23 916 AU/mL at T2, p < 0.0001 for both time-points). T1 values of group A were also significantly higher than T2 values of group D (p < 0.0001). Presence of symptoms, younger age and being female were associated with stronger antibody response. HCW infected in March showed a significantly stronger response (T1: 35 324 AU/mL, IQR 22 003–44 531 AU/mL; T2: 37 648 AU/mL, IQR 27 088–50 451 AU/mL) than those infected in November (T1: 18 499 AU/mL, IQR 11 492–27 283 AU/mL; T2: 23 210 AU/mL, IQR 18 074–36 086 AU/mL, p < 0.0001 for both time-points. Individuals with past SARS-CoV-2 infection had a strong antibody response after one single vaccine shot. A single dose might be sufficient for this group, regardless of the time elapsed since infection; however, the clinical correlation with antibody response needs to be studied.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
5.6
作者：
Tian L;Elsheikh EB;Patrone PN;Kearsley AJ;Gaigalas AK;Inwood S;Lin-Gibson S;Esposito D;Wang L
通讯作者：
Wang L
DOI：
10.2807/1560-7917.es.2021.26.6.2100096
发表时间：
2021-03
期刊：
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
影响因子：
--
作者：
Abu Jabal K;Ben-Amram H;Beiruti K;Batheesh Y;Sussan C;Zarka S;Edelstein M
通讯作者：
Edelstein M
影响因子：
4.5
作者：
Kim SH;Wi YM;Yun SY;Ryu JS;Shin JM;Lee EH;Seo KH;Lee SH;Peck KR
通讯作者：
Peck KR
人类抗体对SARS-COV-2峰值蛋白的受体结合结构域的持久性和衰减在COVID-19患者中。
影响因子：
24.8
作者：
Iyer AS;Jones FK;Nodoushani A;Kelly M;Becker M;Slater D;Mills R;Teng E;Kamruzzaman M;Garcia-Beltran WF;Astudillo M;Yang D;Miller TE;Oliver E;Fischinger S;Atyeo C;Iafrate AJ;Calderwood SB;Lauer SA;Yu J;Li Z;Feldman J;Hauser BM;Caradonna TM;Branda JA;Turbett SE;LaRocque RC;Mellon G;Barouch DH;Schmidt AG;Azman AS;Alter G;Ryan ET;Harris JB;Charles RC
通讯作者：
Charles RC